GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuroscientific Biopharmaceuticals Ltd (ASX:NSB) » Definitions » Intangible Assets

Neuroscientific Biopharmaceuticals (ASX:NSB) Intangible Assets : A$0.43 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Neuroscientific Biopharmaceuticals Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Neuroscientific Biopharmaceuticals's intangible assets for the quarter that ended in Dec. 2023 was A$0.43 Mil.


Neuroscientific Biopharmaceuticals Intangible Assets Historical Data

The historical data trend for Neuroscientific Biopharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuroscientific Biopharmaceuticals Intangible Assets Chart

Neuroscientific Biopharmaceuticals Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Intangible Assets
Get a 7-Day Free Trial 0.42 0.37 0.32 0.27 0.39

Neuroscientific Biopharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.30 0.27 0.43 0.39

Neuroscientific Biopharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Neuroscientific Biopharmaceuticals  (ASX:NSB) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Neuroscientific Biopharmaceuticals Intangible Assets Related Terms

Thank you for viewing the detailed overview of Neuroscientific Biopharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuroscientific Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
a Street, Suite 5, Cottesloe, Perth, WA, AUS, 6011
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.

Neuroscientific Biopharmaceuticals Headlines

No Headlines